Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTER-Tlalpan: HPV Vaccination and Screening
NCT03105856Phase 4Completed
- Sponsor
- Instituto Nacional de Salud Pública
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of human papillomavirus type 16 L1 capsid protein antigen and qHPV vaccine in human papillomavirus infection and Cervical Cancer (CC) (3 arms), sponsored by Instituto Nacional de Salud Pública. Primary endpoint: Incidence 6-month persistent infection of HPV 16 or HPV 18 at 10 years. Started Jan 2017; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenqHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT03105856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105856.